Libellé du chèque à l'ordre de X 
Adresse où envoyer le chèque: 
X

Bonjour <span contenteditable="false" data-custom-variable="{{firstname}}" fr-original-class="fr-deletable styled-tag-chip" fr-original-style style="background-color:rgb(248, 248, 255);border:1px solid rgb(191, 191, 255);border-radius:4px;color:rgb(42, 42, 196);padding:1px 8px;font-size:11px;display:inline-block;margin:0px;overflow-wrap:anywhere;user-select:none;box-sizing:inherit">Prénom, Nous vous remercions du fond du cœur de soutenir notre chaire. Grâce à votre don, nous nous rapprochons d'une victoire contre la leucémie et d'autres formes de cancers du sang. Merci infiniment! Jean Roy MD -Titulaire depuis 2016Maryse and William Brock

Bonjour Prénom,
 
 Nous vous remercions du fond du cœur de vous être inscrit pour collecter des fonds pour notre cause. Vos efforts auront un impact significatif, et nous sommes ravis de vous compter parmi notre équipe de collecte de fonds. 👏
 
 💡 Voici quelques conseils pour partager votre campagne:
 <ol>
 <li>Personnalisez votre histoire : Expliquez pourquoi cette cause est importante pour vous. Les histoires personnelles ont plus de résonance auprès des donateurs potentiels.</li>
 <li>Utilisez les médias sociaux : Publiez au sujet de votre campagne sur Facebook, Instagram, X et LinkedIn. Incluez le lien de la campagne et une image ou une vidéo convaincante.</li>
 <li>Partagez par courriel : Envoyez un courriel personnel à vos amis, à votre famille et à vos collègues pour leur expliquer pourquoi vous collectez des fonds et comment ils peuvent vous aider.</li>
 <li>Mises à jour régulières : Tenez vos supporters informés de vos progrès et des étapes que vous avez franchies. Ils resteront ainsi engagés et seront plus enclins à partager votre campagne.</li>
 </ol>
 Université de Montréal elodie.marteau@umontreal.ca 5146216348

Chaire Maryse et William Brock pour la recherche appliquée en greffe de cellules souches - Campagne 20ème anniversaire

Help Us Cure Leukemia and Transform Blood Cancer Treatments! The Maryse and William Brock Chair for Applied Research in Stem Cell Transplantation is an ambitious project aimed at revolutionizing the treatment of blood cancers, particularly leukemia and multiple myeloma, through clinical research and innovation in hematopoietic stem cell transplantation and cellular therapy. Your support is essential to enable our clinician researchers and medical teams to continue work that has a direct impact on patients' lives. Why is Stem Cell Transplantation Research Crucial? Blood cancers such as leukemia, multiple myeloma, and lymphomas remain among the most complex and difficult diseases to treat. Hematopoietic stem cell transplantation (allogeneic transplant) is one of the most effective treatments for these diseases, but many challenges remain to improve outcomes for these patients. Our Achievements So Far Since the creation of the Maryse and William Brock Chair in December 2016, we have made significant progress:<ul><li style="box-sizing:inherit">Establishment and maintenance of a permanent clinical research unit in hematopoietic stem cell transplantation at HMR.</li><li style="box-sizing:inherit">13 research studies fully designed and conducted at HMR by our researchers: These prospective and retrospective studies have improved stem cell transplant treatments and generated promising results with a direct impact on patient health.</li><li style="box-sizing:inherit">Support for training: We have supported students, including medical students, residents in medicine or hematology, and postdoctoral researchers.</li><li style="box-sizing:inherit">International collaboration: We have established partnerships with prestigious institutions in the United States and Europe to strengthen our ties and participate in promising clinical trials.</li><li style="box-sizing:inherit">Scientific output: Several articles published in scientific journals and presented at national and international conferences (a list of examples of studies and clinical trials supported by the Chair is available at the bottom of this page).</li></ul>What We Aim to Achieve With your support, we have the opportunity to make major advances in the field of stem cell transplantation and cellular therapy, including:<ul><li style="box-sizing:inherit">Improving knowledge of blood cancers: Identifying patients who are more likely to respond well to certain treatments and those at risk of complications.</li><li style="box-sizing:inherit">Developing innovative treatments: Finding more effective and better-suited treatments for each patient.</li><li style="box-sizing:inherit">Accelerating innovation: Launching new clinical studies and trials to improve transplant outcomes and minimize the risk of complications.</li><li style="box-sizing:inherit">Training the next generation of medical professionals: Offering training opportunities for young researchers, doctors, and healthcare professionals so that they can contribute to this medical revolution.</li><li style="box-sizing:inherit">Attracting investment from pharmaceutical companies (trials including new medications).</li><li style="box-sizing:inherit">Promoting international collaborations: Expanding our partnerships to strengthen research and accelerate the implementation of groundbreaking treatments.</li></ul>Why Do We Need Your Help? Despite major advances, clinical research in stem cell transplantation remains costly and is still largely underfunded by the public system. That is why we are turning to you: every donation, no matter the size, directly contributes to advancing our research and improving patients' lives. How Can You Help Us?<ol><li style="box-sizing:inherit">Make a donation: Your financial contribution will help fund clinical studies, innovative treatments, and the recruitment of qualified research staff.</li><li style="box-sizing:inherit">Share our campaign: The more people we reach, the more likely we are to change the fate of thousands of patients. Share this page with your friends, family, and colleagues!</li></ol>Together to Save Lives! We firmly believe that clinical research is the key to defeating blood cancers. But to achieve this, we need your support. Every donation, every share, every contribution brings us closer to a victory against leukemia and other blood cancers. We invite you to join this scientific and human adventure that could change the course of medical history. Together, let’s ensure that every patient has a chance to heal. Make a donation now and transform lives!Thank you for your generosity and commitment! Jean Roy MD - Chairholder since 2016 Maryse and William Brock If you wish to make a donation of more than $5,000, please contact Élodie Marteau, Director of Annual Campaigns at the Alumni and Donors Network of the University of Montreal, at the following email address: <a href="mailto:elodie.marteau@umontreal.ca" style="text-decoration-color:initial;user-select:auto;box-sizing:inherit">elodie.marteau@umontreal.ca</a>  <p style="box-sizing:inherit;width:794.444px;font-style:normal;font-variant-ligatures:normal;font-variant-caps:normal;font-weight:400;orphans:2;text-align:start;text-indent:0px;text-transform:none;widows:2;word-spacing:0px;-webkit-text-stroke-width:0px;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-family:roboto, helvetica, arial, sans-serif;font-size:14px;letter-spacing:0.25px;background-color:rgb(255, 255, 255);margin:0px;line-height:1.5;color:rgb(0, 0, 0)">Examples of studies and clinical trials supported by the Chair•A phase II, open-label study of Bortezomib following nonmyeloablative allogeneic stem cell transplant in patients with high-risk multiple myeloma. •A phase I-II open-label study of reduced intensity conditioning regimen in allogeneic transplant of UM171/fed-batch culture system expanded cord blood in patients with high-risk multiple myeloma. •A phase II, open-label study of lenalidomide and dexamethasone followed by donor lymphocyte infusions in relapsed multiple myeloma following allogeneic stem cell transplant. •Creation of a database on myeloma patients who received an allogeneic transplant at HMR since 2000. •A retrospective study of chronic graft-versus-host disease in myeloma patients who received bortezomib or not after allogeneic transplant. •A phase I-II open-label study of UM171 expanded cord blood in a fed-batch culture system in patients who need an allogeneic hematopoietic stem cell transplant but lack a suitable donor. •Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes.•Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.•Epstein–Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.•Epidemiology and prognosis of young patients with myeloma treated with modern therapies in Canada. •SaFeGreff: a prospective study of women’s health after allogeneic stem cell transplantation.•ABLE3: polyomic biomarker verification in adult chronic graft-versus-host disease.

Dear <span contenteditable="false" data-custom-variable="{{firstname}}" fr-original-class="fr-deletable styled-tag-chip" fr-original-style style="background-color:rgb(248, 248, 255);border:1px solid rgb(191, 191, 255);border-radius:4px;color:rgb(42, 42, 196);padding:1px 8px;font-size:11px;display:inline-block;margin:0px;overflow-wrap:anywhere;user-select:none;box-sizing:inherit">Prénom, We sincerely thank you for supporting our Chair.Thanks to your donation, we are one step closer to a victory against leukemia and other forms of blood cancers. Thank you so much! Jean Roy MD - Chairholder since 2016Maryse and William Brock

Help Us Cure Leukemia and Transform Blood Cancer Treatments! The Maryse and William Brock Chair for Applied Research in Stem Cell Transplantation is an ambitious project aimed at revolutionizing the treatment of blood cancers, particularly leukemia and multiple myeloma, through clinical research and innovation in hematopoietic stem cell transplantation and cellular therapy. Your support is essential to enable our clinician researchers and medical teams to continue work that has a direct impact on patients' lives. Why is Stem Cell Transplantation Research Crucial? Blood cancers such as leukemia, multiple myeloma, and lymphomas remain among the most complex and difficult diseases to treat. Hematopoietic stem cell transplantation (allogeneic transplant) is one of the most effective treatments for these diseases, but many challenges remain to improve outcomes for these patients. Our Achievements So Far Since the creation of the Maryse and William Brock Chair in December 2016, we have made significant progress:<ul><li>Establishment and maintenance of a permanent clinical research unit in hematopoietic stem cell transplantation at HMR.</li><li>13 research studies fully designed and conducted at HMR by our researchers: These prospective and retrospective studies have improved stem cell transplant treatments and generated promising results with a direct impact on patient health.</li><li>Support for training: We have supported students, including medical students, residents in medicine or hematology, and postdoctoral researchers.</li><li>International collaboration: We have established partnerships with prestigious institutions in the United States and Europe to strengthen our ties and participate in promising clinical trials.</li><li>Scientific output: Several articles published in scientific journals and presented at national and international conferences (a list of examples of studies and clinical trials supported by the Chair is available at the bottom of this page).</li></ul>What We Aim to Achieve With your support, we have the opportunity to make major advances in the field of stem cell transplantation and cellular therapy, including:<ul><li>Improving knowledge of blood cancers: Identifying patients who are more likely to respond well to certain treatments and those at risk of complications.</li><li>Developing innovative treatments: Finding more effective and better-suited treatments for each patient.</li><li>Accelerating innovation: Launching new clinical studies and trials to improve transplant outcomes and minimize the risk of complications.</li><li>Training the next generation of medical professionals: Offering training opportunities for young researchers, doctors, and healthcare professionals so that they can contribute to this medical revolution.</li><li>Attracting investment from pharmaceutical companies (trials including new medications).</li><li>Promoting international collaborations: Expanding our partnerships to strengthen research and accelerate the implementation of groundbreaking treatments.</li></ul>Why Do We Need Your Help? Despite major advances, clinical research in stem cell transplantation remains costly and is still largely underfunded by the public system. That is why we are turning to you: every donation, no matter the size, directly contributes to advancing our research and improving patients' lives. How Can You Help Us?<ol><li>Make a donation: Your financial contribution will help fund clinical studies, innovative treatments, and the recruitment of qualified research staff.</li><li>Share our campaign: The more people we reach, the more likely we are to change the fate of thousands of patients. Share this page with your friends, family, and colleagues!</li></ol>Together to Save Lives! We firmly believe that clinical research is the key to defeating blood cancers. But to achieve this, we need your support. Every donation, every share, every contribution brings us closer to a victory against leukemia and other blood cancers. We invite you to join this scientific and human adventure that could change the course of medical history. Together, let’s ensure that every patient has a chance to heal. Make a donation now and transform lives!Thank you for your generosity and commitment! Jean Roy MD - Chairholder since 2016 Maryse and William Brock If you wish to make a donation of more than $5,000, please contact Élodie Marteau, Director of Annual Campaigns at the Alumni and Donors Network of the University of Montreal, at the following email address: <a href="mailto:elodie.marteau@umontreal.ca">elodie.marteau@umontreal.ca</a>  <p style="box-sizing:inherit;width:794.444px;font-style:normal;font-variant-ligatures:normal;font-variant-caps:normal;font-weight:400;orphans:2;text-align:start;text-indent:0px;text-transform:none;widows:2;word-spacing:0px;-webkit-text-stroke-width:0px;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;letter-spacing:0.25px;margin:0px;line-height:1.5;max-width:100%">Examples of studies and clinical trials supported by the Chair•A phase II, open-label study of Bortezomib following nonmyeloablative allogeneic stem cell transplant in patients with high-risk multiple myeloma. •A phase I-II open-label study of reduced intensity conditioning regimen in allogeneic transplant of UM171/fed-batch culture system expanded cord blood in patients with high-risk multiple myeloma. •A phase II, open-label study of lenalidomide and dexamethasone followed by donor lymphocyte infusions in relapsed multiple myeloma following allogeneic stem cell transplant. •Creation of a database on myeloma patients who received an allogeneic transplant at HMR since 2000. •A retrospective study of chronic graft-versus-host disease in myeloma patients who received bortezomib or not after allogeneic transplant. •A phase I-II open-label study of UM171 expanded cord blood in a fed-batch culture system in patients who need an allogeneic hematopoietic stem cell transplant but lack a suitable donor. •Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes.•Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.•Epstein–Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.•Epidemiology and prognosis of young patients with myeloma treated with modern therapies in Canada. •SaFeGreff: a prospective study of women’s health after allogeneic stem cell transplantation.•ABLE3: polyomic biomarker verification in adult chronic graft-versus-host disease.

Maryse and William Brock Chair for Applied Research in Stem Cell Transplantation - 20th Anniversary Campaign

IsFundraiserFormEditDisabled

IsPaymentByPadAllowed

Université de Montréal

### Context Profile for Université de Montréal

1. **Organization Mission & Cause**:
   - **Mission**: Université de Montréal (UdeM) is dedicated to advancing knowledge and fostering innovation through education, research, and community engagement. The institution aims to contribute to the betterment of society by preparing students to become responsible citizens and leaders in their fields.
   - **Cause**: UdeM focuses on a wide range of academic disciplines, promoting research that addresses societal challenges, including health, technology, and the environment.

2. **Type of Activities**:
   - **Academic Programs**: Offers a diverse range of undergraduate and graduate programs across various faculties.
   - **Research Initiatives**: Engages in impactful research projects, often collaborating with industry and community partners.
   - **Community Engagement**: Hosts events, workshops, and outreach programs to connect with the community and promote lifelong learning.
   - **Fundraising Campaigns**: Initiatives like "Kilomètres d'Espoir" support specific causes, such as cancer research, by encouraging community participation in fundraising through physical activities.

3. **Tone of Voice**:
   - The tone of UdeM's communications is **professional yet approachable**, balancing academic rigor with a friendly and inclusive atmosphere. The language is often **inspiring and motivational**, aimed at encouraging engagement and support from the community.

4. **Emoji Usage**:
   - UdeM incorporates emojis in its communications, particularly in fundraising campaigns. Examples include running emojis (🏃🏻‍➡️‍) and heart emojis (🫶), used to convey enthusiasm and emotional connection. Emoji usage appears to be moderate, enhancing the message without overwhelming the text.

5. **Key Facts**:
   - **Founding Info**: Established in 1878, UdeM is one of the largest universities in Canada.
   - **Scale**: It serves a diverse student body and has numerous faculties and research centers.
   - **Impact Metrics**: Engages in significant research output, contributing to advancements in various fields, especially health and technology.
   - **Volunteer Info**: Encourages student and community volunteerism through various programs and initiatives, fostering a culture of giving back.

6. **Writing Guidelines**:
   - **Style**: Use clear, concise language that reflects the institution's academic integrity while remaining accessible to a broad audience.
   - **Engagement**: Incorporate calls to action that inspire participation and support, especially in fundraising contexts.
   - **Inclusivity**: Ensure language is inclusive and welcoming, reflecting the diverse community UdeM serves.
   - **Emotional Appeal**: Utilize storytelling techniques to connect emotionally with the audience, particularly in fundraising campaigns.

This context profile provides a comprehensive overview of Université de Montréal, enabling AI assistants to generate tailored and effective content that aligns with the organization's mission, values, and communication style.

EN

Université de Montréal

Chaire Maryse et William Brock pour la recherche appliquée en greffe de cellules souches - Campagne 20ème anniversaire

Choisir un montant:

$

Vous recevrez un reçu fiscal pour votre don.